About
Therna Biosciences is a San Francisco-based company building RNA-Logix, an 'AI RNA Biologist' platform that pairs generative AI and RNA foundation models with a lab-in-the-loop data engine (Chronos) to design programmable RNA medicines (mRNA, ASO, siRNA) for cardiovascular, metabolic, immunological and rare diseases.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Therna Biosciences
Therna Biosciences is a San Francisco-based company building RNA-Logix, an 'AI RNA Biologist' platform that pairs generative AI and RNA foundation models with a lab-in-the-loop data engine (Chronos) to design programmable RNA medicines (mRNA, ASO, siRNA) for cardiovascular, metabolic, immunological and rare diseases.
$10M
$10M
United States
BusinessLatest roundTotal raisedDate- Integrated Biosciences
Drugs for age-related diseases developed with synthetic biology and AI
Seed · $17M · 2024-10
$17M - Leash Biosciences
Uses AI and machine learning to predict small-molecule drug candidates for any protein
Seed · $9M · 2024-04
$9M - Cheiron
AI-native "drug program operating system" for biopharma teams that models drug R&D programs on a life sciences knowledge graph
Seed · $8M · 2026-07
$8M
China
BusinessLatest roundTotal raisedDate- LigIT
AI-native peptide drug design platform and in-house pipeline
Seed · 2026-10
— - Levinthal Biotech
AI protein design services, with the proprietary all-atom protein design platform Pallatom
Series A · $14M · 2025-12
$14M - Convergen
TRIM21-based TrimTAC targeted protein degradation platform for therapies clearing pathological protein aggregates; pipeline focused on neurodegenerative and autoimmune diseases
Seed · $25M · 2026-08
$25M
Europe
BusinessLatest roundTotal raisedDate- Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M - Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B - Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
25 Life Sciences deals in the last 24 months · 23 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.